## Arwa Younis

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3585707/publications.pdf

Version: 2024-02-01

59	898	10	26
papers	citations	h-index	g-index
61	61	61	1117
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Global, regional, and national burden of ischaemic heart disease and its attributable risk factors, 1990–2017: results from the Global Burden of Disease Study 2017. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 50-60.	1.8	154
2	Use of oral contraceptives in women with congenital long QT syndrome. Heart Rhythm, 2022, 19, 41-48.	0.3	7
3	How to use bipolar and unipolar electrograms for selecting successful ablation sites of ventricular premature contractions. Heart Rhythm, 2022, 19, 1067-1073.	0.3	9
4	Increasing Lesion Dimensions of Bipolar Ablation by Modulating the Surface Area of the Return Electrode. JACC: Clinical Electrophysiology, 2022, 8, 498-510.	1.3	4
5	Big Data in Cardiology: State-of-Art and Future Prospects. Frontiers in Cardiovascular Medicine, 2022, 9, 844296.	1.1	12
6	Outcomes Associated with Introduction of the 5th Generation High-Sensitivity Cardiac Troponin in Patients Presenting with Cardiovascular Disorders. Journal of Emergency Medicine, 2022, , .	0.3	2
7	Transvenous Lead Extraction in Patients with Cardiac Implantable Device: The Impact of Systemic and Local Infection on Clinical Outcomes—An ESC-EHRA ELECTRa (European Lead Extraction Controlled) Registry Substudy. Biology, 2022, 11, 615.	1.3	5
8	Reduction in Ventricular Tachyarrhythmia Burden in Patients Enrolled in the RAIDÂTrial. JACC: Clinical Electrophysiology, 2022, , .	1.3	0
9	Sex hormones and repolarization dynamics during the menstrual cycle in women with congenital long QT syndrome. Heart Rhythm, 2022, 19, 1532-1540.	0.3	6
10	Sex Differences in the Risk of First and Recurrent Ventricular Tachyarrhythmias Among Patients Receiving an Implantable Cardioverter-Defibrillator for Primary Prevention. JAMA Network Open, 2022, 5, e2217153.	2.8	6
11	Risk of arrhythmic events after alcohol septal ablation for hypertrophic cardiomyopathy using continuous implantable cardiac monitoring. Heart Rhythm, 2021, 18, 50-56.	0.3	7
12	CHADS2 and CHA2DS2-VASc scores as predictors of platelet reactivity in acute coronary syndrome. Journal of Cardiology, 2021, 77, 375-379.	0.8	6
13	Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score. European Heart Journal, 2021, 42, 1676-1684.	1.0	61
14	Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. European Journal of Preventive Cardiology, 2021, 28, 1682-1690.	0.8	265
15	Global, Regional, and National Burden of Myocarditis and Cardiomyopathy, 1990–2017. Frontiers in Cardiovascular Medicine, 2021, 8, 610989.	1.1	14
16	Systolic Blood Pressure and Risk for Ventricular Arrhythmia in Patients With an Implantable Cardioverter Defibrillator. American Journal of Cardiology, 2021, 143, 74-79.	0.7	3
17	Risk factors for ventricular tachyarrhythmic events in patients without left bundle branch block who receive cardiac resynchronization therapy. Annals of Noninvasive Electrocardiology, 2021, 26, e12847.	0.5	1
18	Extending the MADIT-ICD benefit score to heterogenous heart failure populations. European Heart Journal, 2021, 42, 4774-4775.	1.0	2

#	Article	IF	CITATIONS
19	Worldwide Trends in Prevalence, Mortality, and Disability-Adjusted Life Years for Hypertensive Heart Disease From 1990 to 2017. Hypertension, 2021, 77, 1223-1233.	1.3	47
20	Ethnic Disparity in Mortality Among Ischemic Heart Disease Patients. A-20 Years Outcome Study From Israel. Frontiers in Cardiovascular Medicine, 2021, 8, 661390.	1.1	2
21	Renal Denervation for Patients With Atrial Fibrillation. Current Cardiology Reports, 2021, 23, 126.	1.3	3
22	Utility of cardiovascular implantable electronic device–derived patient activity to predict clinical outcomes. Heart Rhythm, 2021, 18, 1344-1351.	0.3	3
23	Trends and Regional Variation in Prevalence of Cardiovascular Risk Factors and Association With Socioeconomic Status in Canada, 2005-2016. JAMA Network Open, 2021, 4, e2121443.	2.8	11
24	Pulsed-Field Ablation in Ventricular Myocardium Using a Focal Catheter. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e010375.	2.1	34
25	Hospitalization for HeartÂFailure and Subsequent Ventricular Tachyarrhythmias in Patients With LeftÂVentricular Dysfunction. JACC: Clinical Electrophysiology, 2021, 7, 1099-1107.	1.3	0
26	Outcomes associated with the high sensitivity cardiac troponin testing in patients presenting with non-cardiovascular disorders. American Journal of Emergency Medicine, 2021, 51, 280-284.	0.7	2
27	Regional and socioeconomic disparities in cardiovascular disease in Canada during 2005–2016: evidence from repeated nationwide cross-sectional surveys. BMJ Global Health, 2021, 6, e006809.	2.0	5
28	Predictors and outcomes of atrial tachyarrhythmia among patients with implantable defibrillators. Heart Rhythm, 2020, 17, 553-559.	0.3	5
29	Outcome by Sex in Patients With Long QT Syndrome With an Implantable Cardioverter Defibrillator. Journal of the American Heart Association, 2020, 9, e016398.	1.6	4
30	Applicability of the MADIT-CRT Response Score for Prediction of Long-Term Clinical and Arrhythmic Events by QRS Morphology. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008499.	2.1	1
31	Competing risk analysis of ventricular arrhythmia events in heart failure patients with moderately compromised renal dysfunction. Europace, 2020, 22, 1384-1390.	0.7	8
32	High fitness might be associated with the development of newâ€onset atrial fibrillation in obese nonâ€athletic adults. International Journal of Clinical Practice, 2020, 74, e13638.	0.8	1
33	The role and outcomes of new supraventricular tachycardia among patients with mild heart failure. Journal of Cardiovascular Electrophysiology, 2020, 31, 1099-1104.	0.8	0
34	Cardiac Resynchronization Therapy and Risk of Recurrent Hospitalizations in Patients Without Left Bundle Branch Block. Circulation: Heart Failure, 2020, 13, e006925.	1.6	3
35	Circadian variation and seasonal distribution of implantable defibrillator detected new onset atrial fibrillation. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 1495-1500.	0.5	4
36	Implantable cardioverter-defibrillator programming after first occurrence of ventricular tachycardia in the Multicenter Automatic Defibrillator Implantation Trial–Reduce Inappropriate Therapy (MADIT-RIT). Heart Rhythm O2, 2020, 1, 77-82.	0.6	4

#	Article	lF	CITATIONS
37	Predicting the risk of late futile outcome after transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2020, 96, E695-E702.	0.7	4
38	Marital Status and Long-Term Outcomes in Mild Heart Failure Patients With an Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy With Defibrillator. American Journal of Cardiology, 2020, 125, 1180-1186.	0.7	0
39	Patient selection for wearable cardioverter defibrillator therapy after myocardial infarction: How can we incorporate compliance into decisionâ€making?. Journal of Cardiovascular Electrophysiology, 2020, 31, 1019-1021.	0.8	3
40	CHA2DS2-VASc score performance to predict stroke after acute decompensated heart failure with and without reduced ejection fraction. Europace, 2019, 21, 1639-1645.	0.7	6
41	QRS change in heart failure: When is the right time for cardiac resynchronization therapy?. International Journal of Cardiology, 2019, 296, 87-88.	0.8	0
42	Transvenous lead extraction with laser reduces need for femoral approach during the procedure. PLoS ONE, 2019, 14, e0215589.	1.1	5
43	Risk of death without appropriate defibrillator shock in patients with advanced renal dysfunction. Europace, 2019, 21, 459-464.	0.7	4
44	Relation of Neutrophil to Lymphocyte Ratio to Risk of Incident Atrial Fibrillation. American Journal of Cardiology, 2019, 123, 396-401.	0.7	25
45	The effect of periprocedural beta blocker withdrawal on arrhythmic risk following transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2019, 93, 1361-1366.	0.7	10
46	The Association of Body Mass Index and 20-Year All-Cause Mortality Among Patients With Stable Coronary Artery Disease. Heart Lung and Circulation, 2019, 28, 719-726.	0.2	6
47	Effect of Left Atrial Enlargement on Success Rates of Catheter Ablation of Atrial Fibrillation in Women. Israel Medical Association Journal, 2019, 21, 13-19.	0.1	0
48	Reply to the editor— Disseminated intravascular coagulation as a cause of shock related to device extraction. Heart Rhythm, 2018, 15, e35.	0.3	0
49	Early Referral to Coronary Artery Bypass Grafting Following Acute Coronary Syndrome, Trends and Outcomes from the Acute Coronary Syndrome Israeli Survey (ACSIS) 2000–2010. Heart Lung and Circulation, 2018, 27, 175-182.	0.2	8
50	Donorâ€recipient ethnic mismatching impacts shortâ€and longâ€term results of heart transplantation. Clinical Transplantation, 2018, 32, e13389.	0.8	2
51	Long-Term Outcomes of Iliofemoral Artery Stents after Transfemoral Aortic Valve Replacement. Journal of Vascular and Interventional Radiology, 2018, 29, 1733-1740.	0.2	8
52	The role and outcome of cardiac rehabilitation program in patients with atrial fibrillation. Clinical Cardiology, 2018, 41, 1170-1176.	0.7	23
53	Relation of Atrial Premature Complexes During Exercise Stress Testing to the Risk for the Development of Atrial Fibrillation in Patients Undergoing Cardiac Rehabilitation. American Journal of Cardiology, 2018, 122, 395-399.	0.7	1
54	Post-cardiac Implantable Electronic Devices: Inflammation of the Pocket. Should We Be More Aggressive?. Israel Medical Association Journal, 2018, 20, 539-542.	0.1	0

## ARWA YOUNIS

#	Article	IF	CITATION
55	The addition of vildagliptin to metformin prevents the elevation of interleukin $1  ilde{A}  ilde{Y}$ in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study. Cardiovascular Diabetology, 2017, 16, 69.	2.7	23
56	Characterization of a previously unrecognized clinical phenomenon: Delayed shock after cardiac implantable electronic device extraction. Heart Rhythm, 2017, 14, 1552-1558.	0.3	9
57	Impaired Fasting Glucose Is the Major Determinant of the 20â€Year Mortality Risk Associated With Metabolic Syndrome in Nondiabetic Patients With Stable Coronary Artery Disease. Journal of the American Heart Association, 2017, 6, .	1.6	11
58	Elevated Admission Potassium Levels and 1-Year and 10-Year Mortality Among Patients With Heart Failure. American Journal of the Medical Sciences, 2017, 354, 268-277.	0.4	7
59	Metabolic syndrome is independently associated with increased 20-year mortality in patients with stable coronary artery disease. Cardiovascular Diabetology, 2016, 15, 149.	2.7	42